Drug Profile
Xenon - NeuroproteXeon
Alternative Names: 129Xe; XENEXLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator NeuroproteXeon
- Class Elements; General anaesthetics; Neuroprotectants
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Chronic brain damage
Most Recent Events
- 06 Jul 2021 Invero Pharma acquired assests and intellectual property related to development of xenon from Neuroprotexeon
- 12 Mar 2021 Children's Hospital Medical Center plans a clinical trial for Cystic fibrosis and Bronchiectasis (Diagnosis, In volunteers, In children, In adolescents, In adults, In the elderly) in the USA (Inhalation) in March 2021 (NCT04793867)
- 10 Mar 2021 Phase III development is ongoing for Chronic brain damage in Spain and Germany (EudraCT-2017-002514-32)